TY - JOUR
T1 - The risk of osteoporotic fracture in gastric cancer survivors
T2 - total gastrectomy versus subtotal gastrectomy versus endoscopic treatment
AU - Oh, Hyun Jin
AU - Yoon, Byung Ho
AU - Park, Jung Wee
AU - Jeon, Ye Jhin
AU - Yoo, Bit Na
AU - Bak, Jean Kyung
AU - Ha, Yong Chan
AU - Lee, Young Kyun
N1 - Publisher Copyright:
© 2023, The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association.
PY - 2023/9
Y1 - 2023/9
N2 - Purposes: Previous studies have suggested that there is an increased risk of osteoporotic fracture in gastric cancer survivors. However, the data was not classified according to surgery type. This study investigated the cumulative incidence osteoporotic fracture (OF) in gastric cancer survivors according to treatment modality. Methods: A total of 85,124 gastric cancer survivors during 2008–2016 were included. The type of surgery was classified as total gastrectomy (TG, n = 14,428)/subtotal gastrectomy (SG, n = 52,572)/endoscopic mucosal dissection and endoscopic mucosal resection (ESD/EMR, n = 18,125). The site of osteoporotic fractures included the spine, hip, wrist, and humerus. We examined cumulative incidence using Kaplan–Meier survivor analysis and cox proportional hazards regression analysis to determine the risk factor of OF. Results: The incidence of OF per 100,000 patient year was 2.6, 2.1, 1.8 in TG, SG, ESD/EMR group. The cumulative incidence rate was 2.3% at 3 years, 4.0% at 5 years, and 5.8% at 7 years in gastrectomy group, and 1.8% at 3 years, 3.3% at 5 years in the SG group, and 4.9% at 7 years postoperatively in ESD/EMR group. TG increased the risk of OF compared to patients who underwent SG (HR 1.75, 95% confidence interval [CI] 1.57–1.94), and ESD/EMR (hazard ratio [HR] 2.23, 95% CI 2.14–2.32). Conclusion: Gastric cancer survivors who underwent TG had an increased osteoporotic fracture risk than did SG or ESD/EMR in these patients. The amount of gastric resection and accompanying metabolic changes seemed to mediate such risk. Additional research is needed to establish an optimal strategy for each type of surgery.
AB - Purposes: Previous studies have suggested that there is an increased risk of osteoporotic fracture in gastric cancer survivors. However, the data was not classified according to surgery type. This study investigated the cumulative incidence osteoporotic fracture (OF) in gastric cancer survivors according to treatment modality. Methods: A total of 85,124 gastric cancer survivors during 2008–2016 were included. The type of surgery was classified as total gastrectomy (TG, n = 14,428)/subtotal gastrectomy (SG, n = 52,572)/endoscopic mucosal dissection and endoscopic mucosal resection (ESD/EMR, n = 18,125). The site of osteoporotic fractures included the spine, hip, wrist, and humerus. We examined cumulative incidence using Kaplan–Meier survivor analysis and cox proportional hazards regression analysis to determine the risk factor of OF. Results: The incidence of OF per 100,000 patient year was 2.6, 2.1, 1.8 in TG, SG, ESD/EMR group. The cumulative incidence rate was 2.3% at 3 years, 4.0% at 5 years, and 5.8% at 7 years in gastrectomy group, and 1.8% at 3 years, 3.3% at 5 years in the SG group, and 4.9% at 7 years postoperatively in ESD/EMR group. TG increased the risk of OF compared to patients who underwent SG (HR 1.75, 95% confidence interval [CI] 1.57–1.94), and ESD/EMR (hazard ratio [HR] 2.23, 95% CI 2.14–2.32). Conclusion: Gastric cancer survivors who underwent TG had an increased osteoporotic fracture risk than did SG or ESD/EMR in these patients. The amount of gastric resection and accompanying metabolic changes seemed to mediate such risk. Additional research is needed to establish an optimal strategy for each type of surgery.
KW - Gastrectomy
KW - Gastric cancer
KW - Incidence
KW - Korea
KW - Osteoporotic fracture
UR - http://www.scopus.com/inward/record.url?scp=85160246298&partnerID=8YFLogxK
U2 - 10.1007/s10120-023-01397-y
DO - 10.1007/s10120-023-01397-y
M3 - Article
C2 - 37209225
AN - SCOPUS:85160246298
SN - 1436-3291
VL - 26
SP - 814
EP - 822
JO - Gastric Cancer
JF - Gastric Cancer
IS - 5
ER -